RE:RE:13 & 14enriquesuave wrote: I agree there Fred. If they have enrolled a few more in December (1 per site would be another 4 patients and would be awesome), then we could see some data perhaps fairly early next year on all patients who have reached reached 3 months and for 1st set 9 months data point. Even after 30 days with P5 and 6 from PH1, they knew they had good results IMo, as urine cytology was probably already negative IMO. It's up to Principal Investigators to determine when we may see some data.. Let's get the US up and running and next year will definitely get very interesting. Endocyte Market Cap had gone from $50 Million to $2.1 Billion US in one year . That is 42 times, with the right data anything goes.
fredgoodwinson wrote:
Patients 13 & 14 will be our patients 5 & 6 (i.e.optimally dosed - this time twice).
They may well already have 30-day data for one of them. Only 37 days` after P.6`s single treatment they were able to pronounce:
‘To date the patient has shown no evidence or presence of disease’ This was interpreted as them having confidence at a very early stage (correctly as it turned out) of an enduring complete response.
So there may well be highly price sensitive already available from these recent treatments .Whether they feel inclined or able to publish it independently from the results of the second treatments remains to be seen - probably not.
Even so and although statistically insignificant for many of us these two will be the acid test for the NMIBC Trial. Some time in June?
Agree Enrique. Our big pharma antagonist may just be our US clinical trial impetus with their timely vaccine trial success. Many US hospitals now have their sub-zero fridges in house, plugged in & ready for cold storage. We should be getting two EUA approvals in the next week, then it will be state/county health departments coordinating the vaccine rollouts to all frontline health care providers. Hospital providers are first in line, followed by those in community clinics. Expecting millions of providers will have received their first vaccinations by end of year/early Jan.
Considering the above & the fact that strict hospital safety protocols have been tried & tested for the most part, I don't see increasing trial delays in the US as others have suggested. I wouldn't be surprised to see at least one or two sites ready to enroll & treat by Q1 imo. Mass vaccination should also put a big lid on Covid by 2nd half of next year, at which time I suspect enrollment rates will increase. It also appears that much of the limited hospital capacity of late has been due to staff being out ill or testing positive to Covid, & not just due to the recent increase in Covid cases. Fortunately, illness severity & mortality "rates" have not concomitantly increased. All in all, things are definitely looking brighter for 2021 for both Theralase & the global community. Best of luck.